PCN7 COMPARATIVE EFFECTIVENESS ASSESSMENT OF ERLOTINIB VERSUS GEFITINIB IN FIRST-LINE EGFR ACTIVATING MUTATION POSITIVE NON-SMALL …
B Schwander, J de Castro Carpeño… - Value in …, 2011 - valueinhealthjournal.com
… In this population the EGFR tyrosine kinase inhibitors (TKIs) erlotinib and gefitinib have …
erlotinib PFS HR with each single gefitinib trial, erlotinib was compared to the pooled gefitinib …
erlotinib PFS HR with each single gefitinib trial, erlotinib was compared to the pooled gefitinib …
[HTML][HTML] Comparing gefitinib and traditional chemotherapy for better survival in patients with non-small cell lung cancer: A systematic review
S Kanagalingam, ZU Haq, NV Srinivasan, AI Khan… - Cureus, 2023 - ncbi.nlm.nih.gov
… cohorts [10,16]. In contrast, most such studies did observe PFS prolonging for study cohorts,
… in such clinical cases, with gefitinib/erlotinib being the baseline reference therapy for all …
… in such clinical cases, with gefitinib/erlotinib being the baseline reference therapy for all …
68P Comparison of first-generation EGFR-TKIs (gefitinib, erlotinib, and icotinib) as adjuvant therapy in resected NSCLC patients with sensitive EGFR mutations
W Liang, Q He, C Li, H Liang, B Cheng, J He - Journal of Thoracic Oncology, 2021 - jto.org
… Conclusions: Within our cohort of patients, approximately a quarter of our patients received
adjuvant chemotherapy, relatively similar to what was observed in the ADAURA study. The …
adjuvant chemotherapy, relatively similar to what was observed in the ADAURA study. The …
Predictors of gefitinib outcomes in advanced non-small cell lung cancer (NSCLC): study of a comprehensive panel of molecular markers
M Tiseo, G Rossi, M Capelletti, G Sartori, E Spiritelli… - Lung cancer, 2010 - Elsevier
… Gefitinib and erlotinib, small molecules reversibly binding the ATP pocket in the EGFR …
need validation in future studies. Finally, because this was a single cohort study without a control …
need validation in future studies. Finally, because this was a single cohort study without a control …
EGFR mutation-guided use of afatinib, erlotinib and gefitinib for advanced non-small-cell lung cancer in Hong Kong–A cost-effectiveness analysis
JHS You, WCS Cho, W Ming, Y Li, C Kwan, K Au… - PLoS …, 2021 - journals.plos.org
… A Markov model was designed to simulate outcomes of a hypothetical cohort of advanced
(… -guided use of a TKI (afatinib, erlotinib, and gefitinib). Model outcome measures were direct …
(… -guided use of a TKI (afatinib, erlotinib, and gefitinib). Model outcome measures were direct …
KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib
W Pao, TY Wang, GJ Riely, VA Miller, Q Pan… - PLoS …, 2005 - journals.plos.org
… The latter cohort of patients was part of a clinical trial of erlotinib for patients with
bronchioloalveolar carcinoma. The analysis presented here includes specimens we previously …
bronchioloalveolar carcinoma. The analysis presented here includes specimens we previously …
EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib
W Pao, V Miller, M Zakowski… - Proceedings of the …, 2004 - National Acad Sciences
… , gefitinib (17, 18). Furthermore, we establish that tumors sensitive to a related kinase inhibitor,
erlotinib… When data from the two published reports and this study are used, 25 of 31 (81%) …
erlotinib… When data from the two published reports and this study are used, 25 of 31 (81%) …
… deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non–small cell lung cancer patients treated with gefitinib or erlotinib
DM Jackman, BY Yeap, LV Sequist, N Lindeman… - … Cancer Research, 2006 - AACR
… The aim of the study was to correlate clinical response to gefitinib or erlotinib, time to … A
Kaplan-Meier analysis was used to determine the time to progression for the entire cohort …
Kaplan-Meier analysis was used to determine the time to progression for the entire cohort …
[HTML][HTML] … according to tumor response and shrinkage pattern in patients with EGFR mutation–positive non–small-cell lung cancer treated with gefitinib or erlotinib
M Takeda, I Okamoto, K Nakagawa - Journal of Thoracic Oncology, 2014 - Elsevier
… EGFR-TKIs such as erlotinib and gefitinib are highly effective for the treatment of NSCLC
patients harboring activating EGFR mutations.4, 5, 6, 7 The efficacy of EGFR-TKI treatment …
patients harboring activating EGFR mutations.4, 5, 6, 7 The efficacy of EGFR-TKI treatment …
A phase I dose-escalation study of LY2875358, a bivalent MET antibody, given as monotherapy or in combination with erlotinib or gefitinib in Japanese patients with …
K Yoh, T Doi, H Ohmatsu, T Kojima, H Takahashi… - Investigational New …, 2016 - Springer
… cohort and the LY2875358 2000 mg plus erlotinib and LY2875358 2000 mg plus gefitinib
cohorts (… 2000 mg plus erlotinib and LY2875358 2000 mg plus gefitinib cohorts ranged from …
cohorts (… 2000 mg plus erlotinib and LY2875358 2000 mg plus gefitinib cohorts ranged from …